Although conventional chemotherapy has been one of the major medical advances for some malignancies in the last decades and the introduction of targeted molecular therapies directed against cancer-specific molecules and signaling pathways has increased therapy response and survival rates of patients with a wide variety of solid and hematological malignancies, prognosis of many gastro-intestinal cancers (GI-cancers), especially pancreatic ductal adenocarcinoma, is anymore dismal. To improve our knowledge of basic molecular changes and to develop novel therapeutic strategies, we are investigating disturbed cell cycle regulation, mechanisms of therapeutic resistance, epigenetic changes, altered signaling and metastasis in pancreatic ductal adenocarcinoma and other GI-cancers in vitro and in vivo.
Medical theses ⎮ PhD ⎮ Grant support
MD theses in the research field described are available. Please send an email.
We thank DFG, SFB 824, Deutsche Krebshilfe, Wilhelm-Sander-Stiftung, Rudolf-Bartling-Stiftung and und the DKTK Joint Funding Program for the generous support of our work.